ROCHE PRESENTS POSITIVE PRECLINICAL DATA ON GENMAB ANTIBODY
Genmab A/S announced today that preclinical antibody data developed in collaboration with Roche will be presented today November 8, 2006 in a poster session at the 18th EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics” in Prague, Czech Republic.
The fully human IgG1,? antibody, called R1507, which is in Phase I clinical development, was selected from a large panel of antibodies and was found to be very good at binding to its target, the Insulin-like Growth factor-1 Receptor (IGF-1R). R1507 was shown to block binding of IGF-1 and IGF-2, and to potently inhibit IGF-1R signaling. In addition, R1507 was found to effectively stop tumor cell growth in different animal models.
Source: Press-release Genmab, 08.11.2006.
Read more at the Genmab homepage.